pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-3012Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESРеспираторный статус у больных хроническим бронхитом во время отказа от табакокуренияRespiratory status in chronic bronchitis patients under smoking cessationНовиковК. Ю.NovikovK. Yu.

Москва

СахароваГ. М.SakharovaG. M.

Москва

ЧучалинА. Г.ChuchalinA. G.

Москва

НИИ пульмонологии Минздрава РФRussian Federation200226102021047881Copyright © Новиков К.Ю., Сахарова Г.М., Чучалин А.Г., 20212021Новиков К.Ю., Сахарова Г.М., Чучалин А.Г.Novikov K.Y., Sakharova G.M., Chuchalin A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/3012

Целью исследования являлась оценка динамики изменения функциональных показателей внешнего дыхания (ФВД ) и симптомов хронического бронхита (ХБ) в период отказа от табакокурения и эффективности применения комбинации М-холинолитика и Ы-ацетилцистеина в сочетании с никотинзаместительной терапией с целью профилактики воспалительного процесса. В исследовании участвовали 32 курящих больных ХБ (индекс курящего человека — ИКЧ = 24,7 пачка-лет), которые были разделены на 2 группы (18 и 14 человек). Пациенты 1-й группы получали никотинзаместительную терапию (НЗТ), М-холинолитик (атровент) и N-ацетилцистеин (флуимуцил) в стандартной дозе; пациенты 2-й группы — только НЗТ. Показатели ФВД и симптомы ХБ (кашель, отхождения мокроты, затрудненное дыхание) оценивались в течение'1-го месяца каждую неделю, далее каждый месяц на протяжении 180 дней. Выявлено достоверное снижение FEV1 (7,2%), FVС (12,3%), ММЕF75/25 ( 8,7%) и усиление симптомов ХБ во 2-й группе к 2-3-му дню лечения, которое достигало максимума на 7-й день и длилось 2-3 нед. В 1-й группе значимых изменений выявлено не было.

The aim of the study was to evaluate a dynamics of bronchial inflammation caused by smoking during the cessation period. The inflammation was assessed by lung function parameters (LFP), chronic bronchitis (CB) signs. An efficacy of anticholinergic drug and N-acetylcysteine to prevent the CB exacerbation in addition to nicotine replacement therapy was also checked. The study involved 32 smokers with CB (the smoking history was 24.7 pack-years) who were divided into 2 groups: 18 and 14 persons. The 1st group patients were treated with nicotine replacement therapy (NRP), anticholinergic drug (Atrovent) and N-acetylcysteine (Fluimucil) in standard doses, the 2nd group patients received the NRT only. LFP and CB symptoms (cough, sputum expectoration, shortness of breathing) were evaluated weekly during a month, then every month for 180 days. The 2nd group patients demonstrated a significant decline of FEV1 (7.2%), FVC (12.3%), MMEF75/25 ( 8.7%) and an increase in CB symptoms to the 2nd or 3rd day of the treatment that became maximal to the 7th day and continued for 2 to 3 weeks. The 1st group patients did not have any considerable changes. Conclusion: Atrovent and Fluimucil permit to prevent or reduce the CB exacerbation under the smoking cessation and to enhance the therapy of the nicotine dependency.

ReferencesЧучалин Л.Г., Сахарова Г.М. Болезни легких курящего человека. В кн.: Чучалин А.Г. (ред.) Хронические обструктивные болезни легких. М.: ЗАО "Изд-во БИ Н О М "; 1998. 338-365.Чучалин Л.Г., Сахарова Г.М. Болезни легких курящего человека. В кн.: Чучалин А.Г. (ред.) Хронические обструктивные болезни легких. М.: ЗАО "Изд-во БИ Н О М "; 1998. 338-365.Чучалин А.Г., Сахарова Г.М., Новиков К.Ю. Практическое руководство по лечению табачной зависимости. Рус. мед. журн. 2001; 9: 904-912.Чучалин А.Г., Сахарова Г.М., Новиков К.Ю. Практическое руководство по лечению табачной зависимости. Рус. мед. журн. 2001; 9: 904-912.Fagerstrom К.О. Nicotine addiction and its assessment. Ear Nose Throat J. 1990; 69: 763-775.Fagerstrom К.О. Nicotine addiction and its assessment. Ear Nose Throat J. 1990; 69: 763-775.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis? Management and prevention of chronic obstructive lung disease: N H L B I/ W H O workshop. 2001.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis? Management and prevention of chronic obstructive lung disease: N H L B I/ W H O workshop. 2001.Hsu S.Y., Stone R.B. Coughing frequency in patients with persistent cough assessment cough using a 24 hour ambulatory recorder. Eur. Respir. J. 1994; 7: 1248-1253.Hsu S.Y., Stone R.B. Coughing frequency in patients with persistent cough assessment cough using a 24 hour ambulatory recorder. Eur. Respir. J. 1994; 7: 1248-1253.Lancaster Т., Stead L., Silagy C., Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. Br. Med. J. 2000; 321: 355-358.Lancaster Т., Stead L., Silagy C., Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. Br. Med. J. 2000; 321: 355-358.McAvoy B.H., Kaner E.F., Lock С.Л. et at. Our healthier nation: are general practitioners willing and able to deliver? A survey of attitudes to and involvement in health promotion and lifestyle counselling. Br. J. Gen. Pract. 1999; 49: 187-190.McAvoy B.H., Kaner E.F., Lock С.Л. et at. Our healthier nation: are general practitioners willing and able to deliver? A survey of attitudes to and involvement in health promotion and lifestyle counselling. Br. J. Gen. Pract. 1999; 49: 187-190.McCrory D., Brown C., Gelfand S., Bach P. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001; 119: 1190-1209.McCrory D., Brown C., Gelfand S., Bach P. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001; 119: 1190-1209.Minette A., Aresini G., Sanna-Randaccio F. et at. EC SC questionnaire for the study of respiratory symptoms (1987). Luxembourg, 1988.Minette A., Aresini G., Sanna-Randaccio F. et at. EC SC questionnaire for the study of respiratory symptoms (1987). Luxembourg, 1988.Poole PA., Black P.N. Mucolytic agents for chronic bronchitis (Cochrane review). The Cochrane library, issue 3. Oxford: Update Software Ltd.; 2002.Poole PA., Black P.N. Mucolytic agents for chronic bronchitis (Cochrane review). The Cochrane library, issue 3. Oxford: Update Software Ltd.; 2002.U.S. Surgeon General. The Health consequences of Smoking: chronic obstructive lung disease. D H H S Publication No. 84-50205. U.S. Department of Health and Human Services. Washington, DC; 1984.U.S. Surgeon General. The Health consequences of Smoking: chronic obstructive lung disease. D H H S Publication No. 84-50205. U.S. Department of Health and Human Services. Washington, DC; 1984.West R., McNeill A ., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000; 55: 987.West R., McNeill A ., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000; 55: 987.

The authors declare that there are no conflicts of interest present.